<code id='82067D031E'></code><style id='82067D031E'></style>
    • <acronym id='82067D031E'></acronym>
      <center id='82067D031E'><center id='82067D031E'><tfoot id='82067D031E'></tfoot></center><abbr id='82067D031E'><dir id='82067D031E'><tfoot id='82067D031E'></tfoot><noframes id='82067D031E'>

    • <optgroup id='82067D031E'><strike id='82067D031E'><sup id='82067D031E'></sup></strike><code id='82067D031E'></code></optgroup>
        1. <b id='82067D031E'><label id='82067D031E'><select id='82067D031E'><dt id='82067D031E'><span id='82067D031E'></span></dt></select></label></b><u id='82067D031E'></u>
          <i id='82067D031E'><strike id='82067D031E'><tt id='82067D031E'><pre id='82067D031E'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:31953
          Richard Burr
          North Carolina Senator Richard Burr received strong support from the biotech sector. Gerry Broome/AP

          WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

          North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

          advertisement

          Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Bristol Myers buys into radiopharmaceuticals with RayzeBio
          Bristol Myers buys into radiopharmaceuticals with RayzeBio

          CourtesyBristolMyersSquibbBristolMyersSquibbwillpay$4.1billionforRayzeBio,thecompaniessaidTuesday,bu

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          Hospitals owned by private equity see complications spike 25%

          AdobeThere’sampleevidencethatprivateequitybuyoutsinhealthcaredriveupcosts.Anewstudyshowsqualitydecli